Hematopoiesis News Volume 4.41 | Oct 22 2013

Pten Loss in the Bone Marrow Leads to G-CSF-Mediated HSC Mobilization
Pten conditional deletion using MxCre or Scl-CreER^T leads to splenomegaly and leukemia formation, which occurs after the relocation of normal hematopoietic stem cells (HSCs) from the bone marrow to the spleen. [J Exp Med] Abstract

The Zebrafish Granulocyte Colony Stimulating Factors (Gcsfs): Two Paralogous Cytokines and Their Roles in Hematopoietic Development and Maintenance
In addition to supporting myeloid differentiation, zebrafish Gcsf is required for the specification and proliferation of hematopoietic stem cells, suggesting that Gcsf represents an ancestral cytokine responsible for the broad support of hematopoietic stem and progenitor cells. [Blood] Abstract | Press Release

Poly-L-Lysine Increases the Ex Vivo Expansion and Erythroid Differentiation of Human Hematopoietic Stem Cells, as well as Erythroid Enucleation Efficacy
Investigators employed cell culture plates coated with several concentrations of poly-l-lysine (PLL), a positively charged synthetic amino acid chain. Culture substrates that employed relatively high initial coating concentrations of PLL significantly increased the total number of hematopoietic stem cells during ex vivo expansion of CD34+ cells, as well as erythroid differentiation. [Tissue Eng Part A] Abstract

Characterizing the Lymphopoietic Kinetics and Features of Hematopoietic Progenitors Contained in the Adult Murine Liver In Vivo
Scientists investigated the lymphopoietic capacity of adult liver mononuclear cells and purified liver hematopoietic progenitor cells in vivo. [PLoS One] Full Article

CLINICAL RESEARCH

Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Inpatient Mortality and Survival in Patients Who Received Allogeneic Transplantation Admitted to the Intensive Care Unit
Researchers investigated the prognostic value of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in patients who received transplantation admitted to the intensive care unit. [J Clin Oncol] Abstract

Disabling Immune Tolerance by Programmed Death-1 Blockade with Pidilizumab after Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial
The authors conducted an international Phase II study of pidilizumab, an anti-Programmed Death-1 monoclonal antibody, in patients with diffuse large B-cell lymphoma undergoing autologous hematopoietic stem-cell transplantation, with correlative studies of lymphocyte subsets. [J Clin Oncol] Abstract

Allogeneic Hematopoietic Stem Cell Transplantation in Fanconi Anemia: The EBMT Experience
Researchers analyzed results in 795 Fanconi Anemia patients who underwent first hematopoietic stem cell transplantation between May 1972 and January 2010. [Blood] Abstract

Positive Impact of Chronic Graft-versus-Host Disease on the Outcome of Patients with De Novo Myelodysplastic Syndrome after Allogeneic Hematopoietic Cell Transplantation: A Single-Center Analysis of 115 Patients
To evaluate the impact of graft-versus-host disease and prognostic factors for patients with myelodysplastic syndrome (MDS) after allogeneic hematopoietic cell transplantation (allo-HCT), the authors retrospectively reviewed 115 patients with MDS or acute myeloid leukemia with multilineage dysplasia after allo-HCT at their center. [Eur J Haematol] Abstract

Hematopoietic Stem Cell Injury Induced by Ionizing Radiation
The authors summarized a number of recent findings that provide new insights into the mechanisms whereby ionizing radiation (IR) damages hematopoietic stem cells. These findings will provide new opportunities for developing a mechanism-based strategy to prevent and/or mitigate IR-induced bone marrow suppression. [Antioxid Redox Signal] Abstract

Visit our reviews page to see a complete list of reviews in the hematopoiesis research field.

New Grant to Broaden Exploitation of Promising Immunotherapy to Many Blood Cancers
Researchers from the Center for Cell and Gene Therapy at Baylor College of Medicine, Texas Children’s Hospital and Houston Methodist Hospital have received a $6.25 million, five-year grant from the Leukemia & Lymphoma Society to extend their promising work with T-cell immunotherapies beyond lymphoma to other types of blood cancers including myeloma and acute lymphoblastic leukemia. [Baylor College of Medicine] Press Release

Einstein and Montefiore Receive $25 Million NIH Grant to Support Clinical and Translational Research
Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center have received a $25 million grant from the National Institutes of Health (NIH) for the Harold and Muriel Block Institute for Clinical and Translational Research at Einstein and Montefiore. The two institutions received their initial Clinical and Translational Science Award from the NIH in 2008 to launch this joint collaboration. [Albert Einstein College of Medicine] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

From our sponsor:
View immunology lectures, protocols and other resources on the Human Immunology Portal.

Visit our events page to see a complete list of events in the hematopoiesis research community.

Postdoctoral Position – Human Pluripotent and Hematopoietic Stem Cell Bioinformatics (Albert Einstein College Medicine)

Translational Clinician-Scientist – Stem Cell Transplantation (Boston Children’s Hospital)

Postdoctoral Research Fellow – Human Induced Pluripotent Stem Cell Research (Bioprocessing Technology Institute)

Faculty Positions – Stem Cells and Regenerative Medicine (Baylor College of Medicine)

Postdoctoral Position – Cellular and Genetic Therapies for Hemoglobinopathies (Blood Systems Research Institute)

Postdoctoral Fellow – Mechanisms that Regulate Stem Cell Self-Renewal Using Mouse Blood-Forming Stem Cells (Columbia University)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Technologist – Cell Culture Media & Matrices (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Research Associate – Particle Chemistry (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.